Sanazole as substrate of xanthine oxidase and microsomal NADPH/cytochrome P450 reductase

Pathophysiology

Volumn 8, Issue 2, 2001, Pages 119-127

  Schepetkin, I A ^a   Cherdyntseva, N V ^a   Kagiya, V T ^b  

^a CANCER RESEARCH INSTITUTE   (Russian Federation)

^b Kinki Invention Center   (Japan)

Author keywords

Cytochrome P450 reductase; Hypoxia selective agents; Sanazole; Xanthine oxidase

Indexed keywords

CYTOCHROME C3; METRONIDAZOLE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE FERRIHEMOPROTEIN REDUCTASE; SENAZOLE; TUMOR PROTEIN; XANTHINE; XANTHINE OXIDASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER TISSUE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SELECTIVITY; HYPOXIA; IMMUNOGENICITY; IMMUNOMODULATION; MALE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; RAT;

EID: 0035193671     PISSN: 09284680     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-4680(01)00073-6     Document Type: Article

References (49)

1. Hypoxic cell radiosensitizers as potential adjuvants to conventional chemotherapy for the treatment of cancer
2. Nitroreductase-induced binding of nitroaromatic radiosensitizers to unsaturated lipids: Nitroxyl adducts
3. Binding of H-misonidazole to solid human tumors as a measure of tumor hypoxia
4. Covalent interaction of 5-nitroimidazoles with DNA and protein in vitro: Mechanism of reductive activation
5. Mode of action of metronidazole on anaerobic bacteria and protozoa
6. Binding of the hypoxic tracer [H-3]misonidazole in cerebral ischemia
7. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole
8. TcO(PnAO-1-(2-nitroimidazole)) [BMS-181321], a new technetium-containing nitroimidazole complex for imaging hypoxia: Synthesis, characterization, and xanthine oxidase-catalyzed reduction
9. Heterocyclic mono-N-oxides with potential applications as bioreductive anti-tumour drugs: Part 1. 8-Alkylamino-substituted phenylimidazo [1,2-a] quinoxalines
10. Bioreductive drugs as post-irradiation sensitizers: Comparison of dual function agents with SR4233 and the mitomycin C analogue EO9
11. Hypoxia-selective antitumor agents. 10. Bis(nitroimidazoles) and related bis(nitroheterocycles): Development of derivatives with higher rates of metabolic activation under hypoxia and improved aqueous solubility
12. Immune response to haptenized tumor antigen as possible mechanism of anticancer action of hypoxic bioreductive agents at low doses
13. Molecular enzymology of the reductive bioactivation of hypoxic cell cytotoxins
14. Nitroreductase reactions of the NADPH: Adrenodoxin reductase and the adrenodoxin complex
15. Activation of mitomycin C by NADPH: Cytochrome reductase
16. Chemosensitivity to the indoloquinone EO9 is correlation with DT-diaphorase activity and its gene expression
17. Enzymatic reduction studies of nitroheterocycles
18. Radiosensitization in vitro and in vivo by 3-nitrotriazoles
19. 3-Nitro-1,2,4-triazoles as hypoxia-selective agents
20. Intratumoral and parametrial infusion of a 3-nitrotriazole (AK-2123) in the radiotherapy of the uterine cervix cancer: Stage II-III preliminary positive results
21. Effect of AK-2123 on the immune system in mice
22. Anti-tumor effect of AK-2123 by ultra low dose daily administration in B16 melanoma bearing mice
23. Side chain structure of nitroazoles and anti-tumour activities in B16 melanoma bearing mouse by ultra low dose administration
24. Activation of immunocompetent cells by ultra low dose administration of radiosensitizer AK-2123 in healthy mice
25. The molecular response of mammalian cells to hypoxia and the potential for exploitation in cancer therapy
26. Binding to cellular macromolecules as a possible mechanism for the cytotoxicity of misonidazole
27. Quantitative aspects of the production of superoxide anion radical by milk xanthine oxidase
28. Kinetics of adrenodoxin reductase oxidation by nonphysiological electron acceptors
29. Metabolites from the reduction of metronidazole by xanthine oxidase
30. Anaerobic reduction of nitroimidazoles by reduced flavin mononucleotide and by xanthine oxidase
31. Reduction of fluoromisonidazole, a new imaging agent for hypoxia
32. Nitroimidazole bioreductive metabolism. Quantitation and characterisation of mouse tissue benznidazole nitroreductases in vivo and in vitro
33. N-[5-nitro-2-furfurylidene]-3-amino-2-oxazolidone activation by the human intestinal cell line Caco-2 monitored throughout noninvasive electron spin resonance spectroscopy
34. Reductase and oxygenase activities of semisynthetic flavocytochromes based on cytochrome P450 2B4
35. Lucigenin (bis-N-methylacridonium) as a mediator of superoxide anion production
36. A kinetic study of the reactive capabilities of xanthine oxidase sulfhydryl groups with regard to n-chlormercuribenzoate
37. Regioselective formation of a misonidazole-glutathione conjugate as a function of pH during chemical reduction
38. Delayed-type hypersensitivity reaction
39. Imbalance of purine metabolism in hepatomas of different growth rates as expressed in behavior of xanthine oxidase (EC 1.2.3.2)
40. Activities of DNA turnover and free radical metabolizing enzymes in cancerous human prostate tissue
41. Activities of the enzymes participating in purine and free-radical metabolism in cancerous human colorectal tissues
42. Xanthine oxidase activity of thymocytes affected by X-radiation
43. Mechanisms of regulation of xanthine oxidase conversion in enterocytes under X-radiation
44. Xanthine oxidoreductase in human mammary epithelial cells: Activation in response to inflammatory cytokines
45. Anti-tumour and biochemical effects of purified bovine xanthine oxidase in C3H and C mice
46. A novel cancer therapy based on oxygen radicals
47. Tumor-targeting chemotherapy by a xanthine oxidase-polymer conjugate that generates oxygen-free radicals in tumor tissue
48. Involvement of NADPH: Cytochrome P450 reductase in activation of EO9